Benefits of Oxytocin in OSA Patients Using CPAP
Who is this study for? Adult patients with Obstructive Sleep Apnea
What treatments are being studied? Oxytocin
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Men or women 18 years of age or older.
Locations
United States
Washington, D.c.
Medical Faculty Associates
RECRUITING
Washington D.c.
Contact Information
Primary
Vivek Jain, MD
vjain@mfa.gwu.edu
202-741-2237
Time Frame
Start Date: 2019-03-04
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 40
Treatments
Experimental: Visit 1 Randomization
At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
Experimental: Visit 2 Crossover Randomization
At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
Related Therapeutic Areas
Sponsors
Leads: Vivek Jain
Collaborators: George Washington University